Effects of Obicetrapib, a Potent Oral CETP Inhibitor, on Alzheimer's Disease Biomarkers in 1727 Patients with cardiovascular disease

Abstract

Background: Cholesteryl ester transfer protein (CETP) regulates lipid metabolism, mediating the transfer of cholesteryl esters and triglycerides between LDL and HDL cholesterol particles. The CETP inhibitor, obicetrapib, reduces LDL‐C and increases HDL‐C.